Introduction
============

The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA [@B1]-[@B3]. Besides those from manufacturers, reports can be submitted from health care professionals and the general public. The FAERS structure adheres to the International Safety Reporting Guidance issued by the International Conference on Harmonisation, ICH E2B, and adverse events are coded to terms in the Medical Dictionary for Regulatory Activities (MedDRA) terminology [@B4]. The original system was initiated in 1969; however, reporting markedly increased following the last major revision in 1997 [@B5], [@B6]. To date, the FAERS contains more than 4 million reports and is the largest repository of spontaneously reported adverse events in the world [@B5], [@B6]. The FDA releases data to the general public, and this has allowed us to conduct pharmacoepidemiological studies and/or pharmacovigilance analyses.

Data mining algorithms have been developed for the quantitative detection of signals [@B7]-[@B11]. A signal indicates an association between a drug and an adverse event or drug-associated adverse event, including the proportional reporting ratio (PRR) [@B12], reporting odds ratio (ROR) [@B13], information component (IC) given by a Bayesian confidence propagation neural network [@B14], and empirical Bayes geometric mean (EBGM) [@B15]. Associations with adverse events of interests were previously analyzed for 16 drugs using reports in the FAERS database between 2004 and 2009 [@B16]-[@B22]. Whether an adverse event is detected as a signal has been shown to depend on the algorithms; however, of the 4 methods, the ROR method provided the highest number of signals, while the EBGM method provided the lowest [@B23]. In the present study, the commonality of PRR-, ROR-, IC-, and EBGM-based signals was examined.

Methods
=======

Data were retrieved from the public release of the FAERS database from the first quarter of 2004 through to the end of 2009. The total number of reports obtained was 2,231,029. Duplicated reports were deleted and arbitrary drug names were revised, resulting in a reduction in the number of reports from 2,231,029 to 1,644,220. Signal scores, i.e., the PRR, ROR, IC, and EBGM values, were calculated for 16 unrelated drugs to assess associations with adverse events, including 2 antimicrobials (colistin and tigecycline), 4 HMG-CoA reductase inhibitors (statins) (pravastatin, simvastatin, atorvastatin, and rosuvastatin), 2 proton pump inhibitors (PPIs) (omeprazole and esomeprazole), warfarin, 2 antiplatelets (aspirin and clopidogrel), and 5 anticancer agents (cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, and capecitabine). It is noted that the associations of these drugs with adverse events have already been published [@B16]-[@B22]. All values reported are the mean±standard deviation (SD). The unpaired Student\'s t-test/Welch\'s test or Mann-Whitney\'s U test was used for two-group comparisons of the values. P values of less than 0.05 were considered significant.

Results
=======

Figure [1](#F1){ref-type="fig"} shows the relationship among the PRR-, ROR-, IC-, and EBGM-based signals, which was commonly observed for all 16 drugs. All EBGM-based signals were included in the PRR-based signals as well as IC- or ROR-based ones. The PRR- and IC-based signals were included in the ROR-based ones. Therefore, ROR-based signals could be stratified into 5 groups; signals detected by the ROR only, signals detected by the ROR and PRR, signals detected by the ROR and IC, signals detected by the ROR, PRR, and IC, and signals detected by the 4 methods. Table [1](#T1){ref-type="table"} lists the numbers of signals in the 5 groups. The ratio of the total number of EBGM-based signals to that of signals detected by the ROR only varied from 3.9% with omeprazole to 57.3% with oxaliplatin. The ratio of the total number of EBGM-based signals to that of ROR-based signals varied from 1.7% with omeprazole to 20.5% with oxaliplatin.

Table [2](#T2){ref-type="table"} lists the PRR scores of PRR-based signals. Since PRR-based signals could be divided into 2 groups based on whether adverse events were also detected as signals by the EBGM method (Figure [1](#F1){ref-type="fig"}), the effects of additional detection by the EBGM method on PRR scores was examined. As shown in Table [2](#T2){ref-type="table"}, the scores were significantly larger for 15 of 16 drugs when adverse events were also detected as signals by the EBGM method. Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} show data on the ROR and IC, respectively. The effects of additional detection by the EBGM method found for PRR scores were not observed for the ROR, whereas the IC scores of IC-based signals were the same as the PRR scores of PRR-based signals.

Discussion
==========

Several studies previously compared data mining algorithms [@B13], [@B24]-[@B29]; however, as Bate and Evans recently concluded [@B7], different algorithms have slightly different properties such that one may consequently be preferable in a particular application. If used for pharmacovigilance, data mining algorithms should be assessed from the standpoint of early and timely signal detection [@B30]-[@B33]. Although few studies have published comparative data, Chen et al. recently compared the timing of early signal detection with PRR, ROR, IC, and EBGM using the FAERS database, and concluded that the ROR performed better [@B30]. We previously reported that the ROR method provided the highest number of signals, while the EBGM method provided the lowest [@B23]. The difference in the number of signals can be attributed to a higher rate of false positives or lower ability to detect signals. In the present study, the commonality of signals was clarified, as shown in Figure [1](#F1){ref-type="fig"}. The EBGM method was shown to be the most conservative among the 4 methods, which suggested that it was suitable for pharmacoepidemiological studies. In contrast, the ROR method was shown to be the most comprehensive, indicating its usefulness for pharmacovigilance. These results were consistent with the findings of Chen et al [@B30]. These 4 data mining algorithms were used in our previous studies [@B16]-[@B22], and adverse events were listed as drug-associated, when at least 1 of the 4 indices met the criteria. However, the results shown in Figure [1](#F1){ref-type="fig"} demonstrated that lists of adverse events were only identical when the ROR method was applied, which suggested that care should be taken in interpreting data when signals are not detected by the EBGM method.

Based on the number of signals, 16 drugs could be classified into 4 groups. Group 1 included 2 antimicrobials, which were characterized by the lower number of signals. The total number of co-occurrences with colistin was only 1,491, and 1,906 for tigecycline. These were markedly less than those of the other 14 drugs; from 33,197 with oxaliplatin to 220,194 with atorvastatin. The lower number of signals can be explained by comparatively infrequent use, and, therefore, a smaller number of reports in the database. This is not related to the reliability of the signals.

Group 2 included 4 statins and 2 PPIs characterized by a lower number of EBGM-based signals, and group 3 included warfarin and 2 antiplatelets by a higher number of EBGM-based signals. Group 4 included 5 anticancer agents characterized by a much higher number of EBGM-based signals. The total number of ROR-based signals was similar among drugs in groups 2-4; from 619 with rosuvastatin to 884 with cisplatin. The ROR method is feasible for detecting more signals, including false positives, than the EBGM method. The difference observed in the ratio of EBGM-based to ROR-based signals may reflect whether adverse events are generally found.

A pilot study performed by Hochberg et al. in 2009 concerning drug-versus-drug comparisons revealed that the rank-order of adverse event rates in the FAERS database was consistent with the results of published studies [@B34], which encouraged the use of the database for comparisons. In other investigations, the number of reports with or without normalization by usage or sales during the corresponding period was used to compare drugs [@B35]; however, adverse events are underreported, which may lead to incorrect conclusions [@B36]-[@B38]. Signal scores have also been considered inappropriate for determining the rank-order of drugs in terms of risk; however, few studies have been published to date. In the present study, the EBGM method was shown to be the most conservative among the 4 methods; therefore, it is important to confirm whether this method can provide important information similar to that in well-organized clinical studies.

This study was supported by the Funding Program for Next Generation World-Leading Researchers, Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

![Commonality of signals detected by 4 commonly used data mining algorithms. PRR: proportional reporting ratio; ROR: reporting odds ratio; IC: information component; EBGM: empirical Bayes geometric mean. ROR-based signals were stratified into 5 groups; signals detected by the ROR only, signals detected by the ROR and PRR, signals detected by the ROR and IC, signals detected by the ROR, PRR, and IC, and signals detected by the 4 methods. The numbers of signals in the 5 groups are listed in Table [1](#T1){ref-type="table"}.](ijmsv11p0461g001){#F1}

###### 

Numbers of signals in the 5 groups.

                   ROR only   ROR&PRR   ROR&IC   ROR&PRR&IC   ROR&PRR&IC&EBGM
  ---------------- ---------- --------- -------- ------------ -----------------
  Cisplatin        356        98        49       206          175
  Carboplatin      321        77        80       188          144
  Oxaliplatin      262        64        60       196          150
  Colistin         166        18        1        30           23
  5-Fluorouracil   341        82        62       218          161
  Capecitabine     340        67        51       198          146
  Pravastatin      358        58        125      141          19
  Simvastatin      284        61        268      101          30
  Atorvastatin     304        65        295      164          55
  Rosuvastatin     295        42        97       122          63
  Tigecycline      155        18        2        29           44
  Omeprazole       361        87        244      112          14
  Esomeprazole     348        78        201      99           17
  Warfarin         248        62        157      159          110
  Aspirin          385        86        115      162          100
  Clopidogrel      287        75        185      187          104

PRR: proportional reporting ratio; ROR: reporting odds ratio; IC: information component; EBGM: empirical Bayes geometric mean.

ROR-based signals were stratified into 5 groups; signals detected by the ROR only, signals detected by the ROR and PRR, signals detected by the ROR and IC, signals detected by the ROR, PRR, and IC, and signals detected by the 4 methods.

###### 

PRR scores of PRR-based signals (the signals detected by the PRR method).

                   All   Detected by EBGM   Not detected by EBGM   p                                    
  ---------------- ----- ------------------ ---------------------- ---------------- ----- ------------- ----------
                   N     PRR                N                      PRR              N     PRR           
  Cisplatin        479   8.03 ± 11.29       175                    12.90 ± 16.73    304   5.23 ± 4.36   \< 0.001
  Carboplatin      409   6.80 ± 8.32        144                    10.57 ± 12.25    265   4.76 ± 3.69   \< 0.001
  Oxaliplatin      410   7.72 ± 11.47       150                    11.69 ± 17.16    260   5.43 ± 4.90   \< 0.001
  Colistin         71    29.30 ± 83.82      23                     77.31 ± 136.92   48    6.29 ± 4.66   \< 0.001
  5-Fluorouracil   461   7.52 ± 10.03       161                    11.61 ± 14.90    300   5.33 ± 4.72   \< 0.001
  Capecitabine     411   8.09 ± 13.06       146                    12.07 ± 20.26    265   5.90 ± 5.09   \< 0.001
  Pravastatin      218   4.70 ± 4.26        19                     10.48 ± 8.61     199   4.15 ± 3.11   \< 0.001
  Simvastatin      192   4.50 ± 4.81        30                     8.99 ± 10.33     162   3.66 ± 1.94   \< 0.001
  Atorvastatin     284   3.76 ± 1.93        55                     4.41 ± 1.99      229   3.61 ± 1.89   \< 0.001
  Rosuvastatin     227   5.20 ± 5.77        63                     8.50 ± 9.37      164   3.94 ± 2.65   \< 0.001
  Tigecycline      91    37.88 ± 114.30     44                     72.09 ± 158.16   47    5.85 ± 3.57   \< 0.001
  Omeprazole       213   4.69 ± 5.05        14                     12.29 ± 15.28    199   4.16 ± 2.77   0.003
  Esomeprazole     194   4.65 ± 3.83        17                     7.19 ± 9.50      177   4.41 ± 2.68   0.513
  Warfarin         331   5.28 ± 4.95        110                    7.46 ± 7.38      221   4.19 ± 2.47   \< 0.001
  Aspirin          348   5.56 ± 4.93        100                    8.05 ± 7.39      248   4.56 ± 2.96   \< 0.001
  Clopidogrel      366   4.85 ± 3.79        104                    6.77 ± 5.44      262   4.08 ± 2.52   \< 0.001

PRR-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method.

###### 

ROR scores of ROR-based signals (the signals detected by the ROR method).

                   All   Detected by EBGM   Not detected by EBGM   p                                       
  ---------------- ----- ------------------ ---------------------- ---------------- ----- ---------------- ----------
                   N     ROR                N                      ROR              N     ROR              
  Cisplatin        884   15.75 ± 34.12      175                    13.92 ± 20.63    709   16.20 ± 36.69    0.002
  Carboplatin      810   14.95 ± 43.93      144                    11.07 ± 14.11    666   15.78 ± 47.96    0.001
  Oxaliplatin      732   12.32 ± 31.94      150                    12.41 ± 20.31    582   12.29 ± 34.32    \< 0.001
  Colistin         238   57.84 ± 165.03     23                     78.97 ± 141.67   215   55.58 ± 167.47   0.028
  5-Fluorouracil   864   14.89 ± 37.82      161                    12.34 ± 18.38    703   15.47 ± 40.99    0.001
  Capecitabine     802   17.16 ± 54.77      146                    13.10 ± 25.20    656   18.06 ± 59.35    0.097
  Pravastatin      701   10.00 ± 23.37      19                     10.92 ± 9.30     682   9.97 ± 23.64     0.019
  Simvastatin      744   5.37 ± 7.17        30                     11.03 ± 16.14    714   5.13 ± 6.45      \< 0.001
  Atorvastatin     883   5.14 ± 8.66        55                     4.61 ± 2.24      828   5.18 ± 8.92      \< 0.001
  Rosuvastatin     619   11.87 ± 27.18      63                     8.93 ± 10.68     556   12.21 ± 28.44    0.074
  Tigecycline      248   70.05 ± 381.27     44                     74.82 ± 170.86   204   69.03 ± 413.14   0.008
  Omeprazole       818   6.39 ± 11.04       14                     16.92 ± 26.68    804   6.20 ± 10.51     0.003
  Esomeprazole     743   6.83 ± 10.03       17                     8.05 ± 11.77     726   6.80 ± 9.99      0.308
  Warfarin         736   7.81 ± 13.74       110                    8.36 ± 10.06     626   7.72 ± 14.30     \< 0.001
  Aspirin          848   11.86 ± 35.85      100                    8.38 ± 8.38      748   12.32 ± 38.02    0.033
  Clopidogrel      838   6.20 ± 9.01        104                    7.19 ± 6.26      734   6.06 ± 9.33      \< 0.001

ROR-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method.

###### 

IC scores of IC-based signals (the signals detected by the IC method).

                   All   Detected by EBGM   Not detected by EBGM   p                                 
  ---------------- ----- ------------------ ---------------------- ------------- ----- ------------- ----------
                   N     IC                 N                      IC            N     IC            
  Cisplatin        430   1.64 ± 0.67        175                    2.22 ± 0.55   255   1.24 ± 0.39   \< 0.001
  Carboplatin      412   1.51 ± 0.66        144                    2.15 ± 0.53   268   1.16 ± 0.42   \< 0.001
  Oxaliplatin      406   1.60 ± 0.69        150                    2.22 ± 0.62   256   1.23 ± 0.41   \< 0.001
  Colistin         54    1.82 ± 0.52        23                     2.25 ± 0.47   31    1.51 ± 0.28   \< 0.001
  5-Fluorouracil   441   1.62 ± 0.70        161                    2.32 ± 0.54   280   1.22 ± 0.40   \< 0.001
  Capecitabine     395   1.66 ± 0.70        146                    2.31 ± 0.63   249   1.28 ± 0.41   \< 0.001
  Pravastatin      285   1.03 ± 0.48        19                     1.98 ± 0.28   266   0.96 ± 0.41   \< 0.001
  Simvastatin      399   0.81 ± 0.50        30                     1.96 ± 0.51   369   0.72 ± 0.36   \< 0.001
  Atorvastatin     514   0.92 ± 0.52        55                     1.88 ± 0.41   459   0.80 ± 0.41   \< 0.001
  Rosuvastatin     282   1.27 ± 0.68        63                     2.18 ± 0.60   219   1.00 ± 0.42   \< 0.001
  Tigecycline      75    2.05 ± 0.68        44                     2.44 ± 0.58   31    1.50 ± 0.34   \< 0.001
  Omeprazole       370   0.80 ± 0.50        14                     1.96 ± 0.44   356   0.75 ± 0.44   \< 0.001
  Esomeprazole     317   0.84 ± 0.48        17                     1.78 ± 0.37   300   0.79 ± 0.43   \< 0.001
  Warfarin         426   1.28 ± 0.76        110                    2.19 ± 0.71   316   0.97 ± 0.47   \< 0.001
  Aspirin          377   1.34 ± 0.68        100                    2.18 ± 0.50   277   1.04 ± 0.45   \< 0.001
  Clopidogrel      476   1.20 ± 0.66        104                    2.08 ± 0.56   372   0.95 ± 0.45   \< 0.001

IC-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method.
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